Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Inventiva S.A.NASDAQ: IVA

Financing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Financing cash flow grows 15.6% year over year

Q4 FY2025 financing cash flow of €142.19M rose 15.6% year over year. Over 3 fiscal years it compounded at +84.0% a year.

Context

  • Financing cash flow amounted to 5175.1% of revenue in FY2025, up 3592.3 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
€142.19M— QoQ
Last fiscal yearDec 2025
€232M+59.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.6%——
1 year+59.4%——
3-year CAGR+84.0%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

EUR · from the cash flow

Latest · FY2025
232M EUR
Year-over-year change
+59.4%
4-year CAGR
+73.8%

Financing Cash Flow vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +59.4% is the 5th highest of 10, against a peer median of +49.8%.
  • Financing cash flow amounts to 5175.1% of revenue for IVA, versus a peer median of 385.8%.
IVA Competitors
Financing Cash Flow for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€232M EUR+59.4%+84.0%5175.1%
IVVDInvivyd, Inc.LTM Mar 2026$215.52M USD+89700.8%+652.5%385.8%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.33M USD+380.3%+92.7%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$94.16M USD+226.3%-5.1%287.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$57.73M USD+12.7%+11.7%25658.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$42.1M USD+263.6%—60.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$15.99M USD-76.2%—27094.9%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$15.64M USD-86.7%—881.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$7.05M USD+49.8%+31.2%62.9%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$1.3M USD+41.9%-27.5%—
Peer median (excluding IVA) —+49.8%+21.5%385.8%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Depreciation & Amortization(1.29M)1.7M2.6M5.2M3.22M
Deferred Income Tax(3.27M)(5.26M)(4.74M)(4.8M)(2.3M)
Stock-Based Compensation2.09M2.22M3.97M3.58M26.77M
Change in Working Capital979K5.71M17.31M1.68M6.42M
Accounts Receivables(5.32M)3.84M(5.84M)2.81M816.45K
Inventory(72K)19K(44K)417K0
Accounts Payables7.6M3.54M20M02.46M
Other Working Capital(1.23M)(1.69M)3.19M(1.54M)3.15M
Other Non-Cash Items3.5M4.98M9.68M92.63M205.07M
Operating Cash Flow(47.63M)(44.93M)(81.61M)(85.93M)(100.98M)
Capital Expenditures(534K)(561K)(540K)(333K)(237.26K)
Acquisitions (Net)89K41K000
Purchases of Investments(1.35M)(1K)(8.3M)0(127.69M)
Sales of Investments(89K)9.39M978K9.08M0
Other Investing Activities90K1K131K75.72K(1K)
Investing Cash Flow(1.79M)8.87M(7.73M)8.75M(127.93M)
Debt Repayment(28K)28.44M(4.1M)19.92M(5.98M)
Common Stock Issued25.48M8.83M28.08M57.34M237.74M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(17.73K)(772.47K)5.1M68.33M236.98K
Financing Cash Flow25.45M37.27M29.08M145.59M232M
Effect of Forex Changes4.84M(1.03M)445K1.24M11.08M
Net Change in Cash(19.13M)183K(59.82M)69.65M14.17M
Free Cash Flow(48.16M)(45.49M)(82.15M)(86.26M)(101.22M)

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.